ArticlePLoS neglected tropical diseases2025
Neurological manifestations and MMP8 as a prognostic biomarker in severe fever with thrombocytopenia syndrome.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Predictors of Mortality in Severe Fever with Thrombocytopenia Syndrome: An Updated Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2026Pooled it
- Serum sCD25 predicts mortality and reflects IL-2-driven dysregulation of CD4⁺CD25⁺ T cells in severe fever with thrombocytopenia syndrome.Tropical medicine and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSevere fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality. Neurological symptoms are increasingly recognized as critical predictors of poor outcomevs, but their mechanisms remain unclear. This study aims to explore relevant mechanisms and identify biomarkers.
methodsThis study utilized three distinct SFTS patient cohorts. First, 15 hospitalized patients from April 21 to August 2, 2024 were prospectively enrolled, with blood samples collected during hospitalization for RNA sequencing of peripheral blood mononuclear cells (PBMCs) to identify differentially expressed genes (DEGs). Second, we established a single-center retrospective cohort comprising 103 SFTS patients (admitted 2021-2024) to analyze clinical data pertaining to central nervous system (CNS) symptoms and patient outcomes. Third, to quantitatively assess serum matrix metalloproteinase-8 (MMP8) levels, we analyzed a total of 151 serum samples obtained from patients across two independent centers using enzyme-linked immunosorbent assay (ELISA).
resultsRNA sequencing analysis between the recovered group and deceased group revealed significant alterations in central nervous system (CNS)-related pathways. Clinical data from 103 SFTS patients showed the deceased group had significantly higher rates of neurological symptoms vs the recovered group over the full course: consciousness disorders (88.89% vs 23.53%, P < 0.001) and convulsions (27.78% vs 3.53%, P = 0.003). Patients with these symptoms had both upregulated MMP8 gene expression and elevated serum MMP8 levels. Elevated serum MMP8 strongly correlated with fatal outcomes (AUC = 0.821, 95% CI: 0.681-0.962; P = 0.008). Multivariate Cox analysis confirmed MMP8 as an independent mortality predictor (HR = 1.060, 95% CI: 1.010-1.112). The MMP8-incorporated multivariable Cox model showed good discriminative ability in the external validation cohort (AUC = 0.843, 95% CI: 0.723-0.962).
conclusionsNeurological symptoms during the early stages of SFTS are strongly associated with patient outcomes. MMP8 may serve as a potential biomarker for SFTS prognosis. The integration of clinical neurological symptoms and MMP8 measurement offers a novel framework for improving prognostic accuracy and guiding personalized management strategies in SFTS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.